Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma

Cancer Research

Volumn 74, Issue 2, 2014, Pages 543-551

  Okazaki, Hiroyuki ^a   Matsunaga, Naoya ^a   Fujioka, Takashi ^a   Okazaki, Fumiyasu ^a   Akagawa, Yui ^a   Tsurudome, Yuuya ^a   Ono, Mayumi ^a   Kuwano, Michihiko ^a   Koyanagi, Satoru ^a   Ohdo, Shigehiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FBXW7 GENE; GENE; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSCILLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; TUMOR GROWTH; UBIQUITINATION;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; CIRCADIAN RHYTHM; F-BOX PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; OSCILLOMETRY; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84892915652     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3241     Document Type: Article

References (33)

1. Stephan FK, Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. Proc Natl Acad Sci U S A 1972;69:1583-6.
2. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science 1998;280:1564-9.
3. Alvarez JD, Sehgal A. Circadian rhythms: finer clock control. Nature 2002;419:798-9.
4. Kume K, Zylka MJ, Sriram S, Shearman LP, Weaver DR, Jin X, et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 1999;98:193-205.
5. Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, McNamara P, et al. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron 2004;43:527-37.
6. Wuarin J, Schibler U. Expression of the liver-enriched transcriptional activator protein DBP follows a stringent circadian rhythm. Cell 1990;63:1257-66.
7. Sato TK, Yamada RG, Ukai H, Baggs JE, Miraglia LJ, Kobayashi TJ, et al. Feedback repression is required for mammalian circadian clock function. Nat Genet 2006;38:312-9.
8. Wood PA, Du-Quiton J, You S, Hrushesky WJ. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 2006;5:2023-33.
9. Levi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 2006;17:611-21.
10. Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ. Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther 2003;2:105-11.
11. Ohdo S. Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety. Drug Saf 2003;26:999-1010.
12. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999;344:427-31.
13. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999;59:3581-7.
14. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996;56:3895-7.
15. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-61.
16. Pitt M, Crathorne L, Moxham T, Bond M, Hyde C. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. Health Technol Assess 2010;14 Suppl 2:41-6.
17. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006;31:342-8.
18. Haghighat A, Mader S, Pause A, Sonenberg N. Repression of capdependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 1995;14:5701-9.
19. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997;272:26457-63.
20. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011;146:408-20.
21. Finger DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-87.
22. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol 2004;36:2445-62.
23. Khapre RV, Samsa WE, Kondratov RV. Circadian regulation of cell cycle: molecular connections between aging and the circadian clock. Ann Med 2010;42:404-15.
24. Miyazaki K, Wakabayashi M, Hara Y, Ishida N. Tumor growth suppression in vivo by overexpression of the circadian component, PER2. Genes Cells 2010;15:351-8.
25. Khoschsorur G. Simultaneous measurement of sirolimus and everolimus in whole blood by HPLC with ultraviolet detection. Clin Chem 2005;51:1721-4.
26. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, Del Rosario R, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-502.
27. Nakagawa H, Takiguchi T, Nakamura M, Furuyama A, Koyanagi S, Aramaki H, et al. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. Biochem Pharmacol 2006;72:1237-45.
28. Kuramoto Y, Hata K, Koyanagi S, Ohdo S, Shimeno H, Soeda S. Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones. Biochem Pharmacol 2005;71:1155-61.
29. Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003;63:7277-83.
30. Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, Godinho SI, et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 2007;316:900-4.
31. Siepka SM, Yoo SH, Park J, Song W, Kumar V, Hu Y, et al. Circadian mutant overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression. Cell 2007;129:1011-23.
32. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294:173-7.
33. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-myc is mediated by the F-box protein Fbw7. EMBO J 2004;23:2116-25.